Optas LLC Buys Shares of 18,097 Haleon plc (NYSE:HLN)

Optas LLC purchased a new position in shares of Haleon plc (NYSE:HLN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,097 shares of the company’s stock, valued at approximately $173,000.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC increased its position in Haleon by 5.8% during the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after purchasing an additional 5,768,117 shares during the period. Wellington Management Group LLP increased its holdings in Haleon by 49.9% during the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after buying an additional 3,046,841 shares during the period. JPMorgan Chase & Co. raised its stake in Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after buying an additional 1,026,939 shares in the last quarter. Natixis Advisors LLC lifted its holdings in Haleon by 142.5% during the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after buying an additional 866,070 shares during the period. Finally, Jane Street Group LLC boosted its position in Haleon by 1,689.4% during the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after acquiring an additional 250,169 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on HLN shares. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Haleon currently has an average rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Stock Up 0.6 %

HLN stock opened at $9.54 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The stock has a market capitalization of $43.16 billion, a PE ratio of 28.04, a price-to-earnings-growth ratio of 2.69 and a beta of 0.28. The firm has a 50 day moving average of $9.54 and a 200 day moving average of $9.77.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.